For a disease that has been recognized since the days of Hippocrates, we are finally making some progress towards understanding systemic lupus erythematosus (SLE) and how to tame the wolf. Listed below are the top 5 studies and their summaries presented at the recent EULAR e-Congress confer
All News
Article
Article
Flares in ANCA-associated vasculitis are difficult to predict, but serum calprotectin may help predict relapse and renal failure, according to data presented at the EULAR 2020 virtual meeting this week.
Article
Every time a big scientific meeting ends I ask myself a question: how is it going to affect the way I treat my patients? This year the question pertains to management of axial spondyloarthropathies and psoriatic arthritis.
#EULAR2020 #op0054 DISCOVER 1&2 rct results for Guselkumab in PsA w/ sacroiliitis: significantly better BaSDAI, improved spinal pain& ASDAS-CRP vs PBO suggestive of good clincial efficacy. No radiographic data @RheumNow https://t.co/MeXV08hcBU
#EULAR2020 #op0051 presence of Structural Enthrseal Lesions (SEL) in PSO associated w/higher risk of progression to PsA: 37.5%If SEL present vs 3.4% no SEL/no arthalgia& 15.2% no SEL/+arthralgia. Highest risk in PSO w/SEL+arthralgia at 42.8% @RheumNow https://t.co/7knYXeap7l
#EULAR2020 #op0050 RCT ph4 results: in inadequately controlled PsA addition of ADA results in better outcomes in terms MDA, ACR20, PASI75, HAQ-DI&LEI as opposed to MTX dose escalation @RheumNow https://t.co/iMgCkRawCl
Not missing being torn between ballroom 1 and exhibit hall 2 š #EULAR2020 #onlinelearning #VirtualConference @RheumNow https://t.co/rHLquYPjW5
#EULAR2020 #LB0001 SELECT-PsA-1 Upadacitinib vs PBO vs ADA: UPA 15/30 mg non-inferior &UPA 30 superior to ADA for ACR20. At wk12 ACR 20 70.6% UPA15, 78.5% UPA30 vs 36.2%PBO & 65%ADA. Better ACR50/70 &MDA va PBO. No new safety signals. @RheumNow https://t.co/QZkMdoqXEC
#EULAR2020 #op0015 relationship btw sUA &mortality in the US: increased mortality in M w/ low sUA but not F. could be attributed to uricosuric effect of uncontrolled hyperglycemia ( high incidence of DM)? Lower Alzheimerās mortality in M&F w/high sUA. @RheumNow https://t.co/E4HVXASKYy
#EULAR2020 #op0079 ASAS-MRI group offers updated definition of the structural lesions in SI joints in AxSpA:
-erosion in >=2 consecutive slices or in >=3 SIJ quadrants
- fat lesions w/depth >1cm in >=1SIJ quadrant
are high priority candidates @RheumNow https://t.co/EU1WWqJ4h3
#EULAR2020 #op0201 nationwide cohort study: higher incidence of dementia in SLE (3.9/1000pys) vs non-SLE ( 2.73/1000pys). HR 1.43. In SLE risk of Alzheimerās 1.4x &risk of vascular dementia 1.6x Higher than non-SLE cohort. Further studies to identify mechanism needed @RheumNow
#EULAR2020 #op0192 UK Biobank and IMPALA studies: metabolic body composition of PsA pts w/increased VAT,ectopic liver fat distribution & ā¬ļø abdominal fat index associated w/increased risk of CHD&T2DM @RheumNow https://t.co/CwwAB2yUid
#EULAR2020 #op0182 delayed gadolinium-enhanced MRI study reveals proteoglycan loss in articulate cartilage in PsA associated w/severity of periarticular inflammation, synovitis &flexor tenosynovits but not bone erosion or prolypheration. @RheumNow https://t.co/ZJBDnZuYbB
#EULAR2020 #op0202-hpr š¬š§ study remind that resistant training benefits patients with inflammatory arthritides: improved function, wellbeing, self-efficacy, strength and fatigue.improved balance&endurance helps prevent falls @RheumNow https://t.co/MH7VD6zH9t
#EULAR2020 #op0143 a nationwide study concludes GCA pts at higher risk for sarcoma (HR 2.14), kidney cancer (1.6), hematological malignancies (HL2.42&non-HL1.66). Overall cancer HR 1.29. Time to diagnosis shorter in GCA (~48mo) vs controls (~58mo) @RheumNow https://t.co/obAlZw2gei


